Breast cancer is detected through a combination of screening tests, imaging, and tissue sampling, with mammography serving as the primary tool for most people. The U.S. Preventive Services Task Force recommends mammograms every two years starting at age 40 and continuing through age 74. But mammography is just one step in a detection process that can involve several technologies, each suited to different situations.
Mammography and 3D Imaging
A standard mammogram uses low-dose X-rays to create a flat, two-dimensional image of the breast. It remains the most widely used screening tool and catches the majority of breast cancers, particularly in women with less dense breast tissue. In fatty breasts, mammography sensitivity reaches as high as 93%.
Digital breast tomosynthesis, commonly called 3D mammography, takes multiple images from different angles and reconstructs them into thin slices, similar to flipping through pages of a book. This makes it easier to spot small tumors that might be hidden behind overlapping tissue in a traditional 2D image. In a study comparing the two approaches, 3D mammography paired with artificial intelligence detected 94.3% of individual lesions, compared to 72.6% for standard 2D mammography with conventional computer-assisted detection. The 3D approach also produced far fewer false alarms: roughly one false mark per exam versus more than three.
Why Breast Density Matters
Dense breast tissue and cancer both appear white on a mammogram, which means dense tissue can hide tumors the way a snowball disappears against a white wall. This is a significant problem. Mammography sensitivity drops from around 93% in fatty breasts to as low as 30% in extremely dense breasts. At the same time, false-positive results more than double, rising from about 11 per 1,000 exams to 24 per 1,000.
Nearly half of women have dense breasts, and many states now require that mammogram reports include a density notification. If you have dense breast tissue, your doctor may recommend supplemental screening with ultrasound, contrast-enhanced mammography, or MRI.
Ultrasound and MRI
Breast ultrasound uses sound waves to produce images and is particularly useful for evaluating lumps found on a mammogram or during a physical exam. It can distinguish between fluid-filled cysts (which are almost always benign) and solid masses that may need further investigation. Ultrasound is often the first follow-up test after an abnormal mammogram, especially for women with dense breast tissue.
MRI is the most sensitive imaging tool for breast cancer. It works by detecting differences in blood flow: cancerous tissue tends to develop its own blood supply, and MRI can pick up those vascular patterns to distinguish malignant from benign growths, achieving about 84% specificity in some studies. The tradeoff is a higher rate of false positives, which can lead to unnecessary biopsies and anxiety. For this reason, MRI is typically reserved for women at high risk, such as those with known genetic mutations, a strong family history, or prior chest radiation. Abbreviated MRI protocols, which take less time and cost less, are being used more widely as a middle-ground option for supplemental screening.
Physical Signs to Watch For
Not all breast cancers are found on a screening test. Some are discovered because of a physical change you can see or feel. Signs worth paying attention to include:
- A lump or mass in the breast or armpit, which may or may not be painful
- Skin changes such as redness, thickening, dimpling, or puckering that gives the skin an orange-peel texture
- Nipple changes including inversion (turning inward), pulling to one side, scaling, or spontaneous discharge
These symptoms don’t automatically mean cancer. Many are caused by benign conditions. But any persistent, unexplained change in the breast deserves evaluation.
Biopsy: Confirming the Diagnosis
Imaging can raise suspicion, but only a biopsy can confirm whether cancer is present. During a biopsy, a small sample of tissue is removed and examined under a microscope. There are two main needle-based approaches.
Fine needle aspiration uses a thin needle (about the width of a standard blood-draw needle) to extract individual cells from a suspicious area. It’s quick and minimally invasive, but its accuracy varies widely, with sensitivity ranging from 35% to 95% depending on the situation. It also can’t distinguish between invasive cancer and non-invasive types like ductal carcinoma in situ, because the sample doesn’t preserve the tissue’s structure.
Core needle biopsy uses a larger, hollow needle to remove a small cylinder of tissue. This preserves the architecture of the cells, giving pathologists much more information. Sensitivity ranges from 85% to 100%, with specificity between 86% and 100%. Core needle biopsy is now the preferred method for most breast abnormalities because it provides enough tissue for the critical next step: receptor testing.
Receptor Testing and Cancer Subtype
Once cancer is confirmed, the biopsy sample is tested for three key receptors that sit on or inside cancer cells. These results shape every treatment decision that follows.
The first two are estrogen receptor (ER) and progesterone receptor (PR). Cancers that test positive for these receptors are fueled by hormones and can be treated with therapies that block hormonal signals. The third is HER2, a protein that promotes cell growth. Cancers that overproduce HER2 tend to be more aggressive but respond to targeted therapies designed specifically for that protein.
Together, these three markers sort breast cancer into subtypes. A cancer that is ER-positive and HER2-negative behaves very differently from one that is triple-negative (lacking all three receptors), and the treatment plans reflect that. This is why core needle biopsy, which provides enough tissue for receptor analysis, is so much more useful than fine needle aspiration for diagnosis.
Genetic Risk Assessment
Some breast cancers are linked to inherited mutations in the BRCA1 and BRCA2 genes. People who carry these mutations face a substantially higher lifetime risk of developing breast cancer, and detection strategies for them start earlier and include MRI screening alongside mammography.
Genetic testing isn’t recommended for everyone. It’s most appropriate when your personal or family history suggests an inherited pattern: multiple relatives with breast or ovarian cancer, cancer diagnosed at a young age, or ancestry associated with higher rates of BRCA mutations (such as Ashkenazi Jewish heritage). The process typically begins with a formal risk assessment tool, followed by genetic counseling to help interpret what the results would mean before any blood test is drawn.
Breast Cancer Detection in Men
Breast cancer in men is rare, accounting for less than 1% of all cases, but it does occur and is often caught later because most men aren’t aware it’s possible. The most common sign is a painless lump or thickening on the chest wall. Other signs mirror those in women: skin dimpling or puckering, nipple inversion, scaling around the nipple, or nipple discharge. Because men aren’t included in routine screening programs, most male breast cancers are detected through physical symptoms rather than imaging.
How AI Is Changing Screening
Artificial intelligence is increasingly being integrated into mammography reading. In the MASAI trial, a large randomized study, AI-supported screening achieved 80.5% sensitivity compared to 73.8% for standard double reading by two radiologists. Specificity remained identical at 98.5% for both groups, meaning AI improved cancer detection without increasing false positives. The AI-supported group also had fewer interval cancers (cancers that appear between scheduled screenings), and those that did appear tended to be smaller and less aggressive. AI also reduced the reading workload for radiologists, potentially making screening programs more sustainable as demand grows.